About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT04168242

Scalp Cooling in Gynecologic Cancer Patients

In gynecologic cancers, many common chemotherapy agents can lead to chemotherapy-induced alopecia. Currently scalp cooling is the most well studied preventive measure. However, its acceptability and i...

Lead sponsor: The University of Hong Kong•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

The University of Hong Kong

Dynamic scalp cooling system prevents alopecia by inducing vasoconstriction leading to a reduction of scalp blood flow, thus reducing the delivery of cytotoxic drugs to the hair follicles and reducing follicular metabolic activities. One recent meta-analysis included 10 studies showed that the efficacy was 43% in general.

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•1. Patients must be at least 18 years old.
•2. Patients with primary gynecologic cancers.
•3. Patients who are going to receive at least four cycles of chemotherapy that are known to induce alopecia, such as carboplatin, paclitaxel, taxotere, topotecan, etoposide, vincristine and ifosfamide.
•4. Patients who are fit to give informed consent.

Exclusion Criteria

•1. Patients who have pre-existing alopecia of CTCAE v5.0 grade 1 or above will be excluded.
•2. Patients who have the following conditions will be excluded:
•1. migraine
•2. scalp or brain metastasis
•3. hypothyroidism
•4. uncontrolled diabetes
•5. liver and / or renal derangement (where liver enzymes and / or creatinine are 1.5x more than upper normal limit)
•6. severe untreated anaemia
•7. cold sensitivity
•8. cold agglutinin disease, cryoglobulinemia, or cryofibrinogenemia
•3. Patients who had brain irradiation.
•4. Patients who have documented psychiatric disorders will be excluded.
•5. Patients who are pregnant.

Related studies

CARE Tool Study Aim 3

NCT07296887 · Gynecologic Cancer, Prostate Cancer, and more

RECRUITINGPhase 2

A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

NCT05787561 · Mesonephric Gynecologic Cancer

RECRUITINGPhase 1/2

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

NCT05559879 · Gynecologic Cancer, Carcinoma, and more

Avera Cancer Sequencing and Analytics Protocol (ASAP)

NCT05142033 · Cancer, Cancer Diagnosis, and more

RECRUITINGPhase 2

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

NCT07447050 · Breast Cancer, Sarcoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 20, 2023Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment80

Start dateNov 2019

Last updatedDec 20, 2023

Condition

Gynecologic Cancer Chemotherapy-Induced Change

Locations shown

The University of Hong Kong

Hong Kong

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 20, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions